CMS

CMS rule cuts reimbursement for new Part B drugs
CMS rule cuts reimbursement for new Part B drugs
BioCentury
Medicare Part B
CMS
reimbursement
physician-administered drugs
Flag link:
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
Fierce Pharma
CMS
UnitedHealthcare
Medicare
JNJ
Remicade
biosimilars
Pfizer
Merck
Flag link:
Medtech reporting would change under new opioid law
Medtech reporting would change under new opioid law
Mass Device
opioids
opioid crisis
Medicare
Medicaid
CMS
devices
Flag link:
Standardization Of Drug Compendia That Support Off-Label Use Reimbursement Of Cancer Drugs
Standardization Of Drug Compendia That Support Off-Label Use Reimbursement Of Cancer Drugs
Forbes
off-label
oncology
oncologists
cancer
CMS
Flag link:
Medicare Part D to allow indication-driven formularies
Medicare Part D to allow indication-driven formularies
BioCentury
Medicare
Medicare Part D
CMS
formulary
Flag link:
No, Massachusetts, you can't run a PBM-style Medicaid formulary, feds say
No, Massachusetts, you can't run a PBM-style Medicaid formulary, feds say
Fierce Pharma
drug pricing
Massachusetts
Medicaid
CMS
PBMs
Flag link:
Pharma, payers clash over CMS Part D drug rebate plan
Pharma, payers clash over CMS Part D drug rebate plan
HealthcareDive
payers
CMS
Medicare Part D
Medicare
drug rebates
Flag link:
Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B
Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B
RAPS.org
AbbVie
Amgen
Humira
biosimilars
Medicare
Medicaid
CMS
Flag link:
Why regional reimbursement strategies could be right for medtech
Why regional reimbursement strategies could be right for medtech
Medical Design and Outsourcing
devices
reimbursement
CMS
Flag link:
Health Spending Projections By CMS Could Influence AHCA Votes
Health Spending Projections By CMS Could Influence AHCA Votes
Forbes
healthcare reform
CMS
American Health Care Act
Flag link:
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Seeking Alpha
Mylan Labs
EpiPens
CMS
rebates
Medicare
Medicaid
Flag link:
CMS Releases Final Medicaid Rebate Rule
CMS Releases Final Medicaid Rebate Rule
FDA Law Blog
Medicaid
CMS
rebates
Flag link:
A proposal for biosimilar reimbursement sparks outrage
A proposal for biosimilar reimbursement sparks outrage
Pharmalot
biosimilars
CMS
reimbursement
Flag link:
Dendreon And CMS Under SEC Scrutiny Over Insider Trading
Dendreon And CMS Under SEC Scrutiny Over Insider Trading
Bidness Etc.
Dendreon
CMS
SEC
insider trading
Flag link:
Pharma, Physicians And 'Open Payments': Moving From Data To Understanding
Pharma, Physicians And 'Open Payments': Moving From Data To Understanding
Forbes
CMS
physician payments
Physician Payment Sunshine Act
Flag link:
Breakthrough Pathway: Lone Bright Spot Among the Macro Trends for Medical Devices?
Breakthrough Pathway: Lone Bright Spot Among the Macro Trends for Medical Devices?
Morning Consult
devices
breakthrough pathway
innovation
FDA
CMS
Flag link:
Better Late Than Never: CMS Improves The Doctor Payment Website
Better Late Than Never: CMS Improves The Doctor Payment Website
WSJ Pharmalot
CMS
Medicare
Medicaid
physician payments
Physician Payment Sunshine Act
Flag link:
CMS Asked to Eliminate Some Payments From Sunshine Database
CMS Asked to Eliminate Some Payments From Sunshine Database
WSJ Pharmalot
physician payments
Physician Payment Sunshine Act
CMS
Flag link:
Lilly Backs Lawsuit Against CMS Over its Alzheimer’s Diagnostic Drug
Lilly Backs Lawsuit Against CMS Over its Alzheimer’s Diagnostic Drug
WSJ Pharmalot
Eli Lilly
Alzheimer's disease
Amyvid
CMS
Medicare
Medicaid
Flag link:
CMS Denies Amyvid Coverage: A Bigger Message To Biopharma
CMS Denies Amyvid Coverage: A Bigger Message To Biopharma
Elsevier Business Intelligence
Eli Lilly
CMS
Amyvid
Alzheimer's disease
Flag link:

Pages